- Home
- IMUX
IMUX
Immunic Inc.
as 11-15-2024 4:00pm EST
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 110.8M | IPO Year: | N/A |
| Target Price: | $13.20 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.97 - $2.11 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Immunic Inc. News
IMUX Breaking Stock News: Dive into IMUX Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Insider Buys Additional US$100k In Immunic Stock
TipRanks
3 days ago
Immunic announces publication of IMU-856 data
PR Newswire
4 days ago
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
GuruFocus.com
8 days ago
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges
Associated Press Finance
10 days ago
Immunic: Q3 Earnings Snapshot
PR Newswire
10 days ago
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
18 days ago
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
PR Newswire
20 days ago
Immunic to Participate in Industry, Scientific and Investor Conferences in November
Compare IMUX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMUX Immunic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.